Best Peptides for Fat Loss 2026: Complete Ranking (by Mechanism & Evidence)

Understanding Fat Loss Mechanisms: Three Distinct Pathways

Before ranking individual compounds, you need to understand the three primary mechanisms through which peptides reduce body fat:

Pathway 1: Appetite Suppression + Metabolic Signaling (GLP-1 Agonists)

GLP-1 (Glucagon-Like Peptide-1) receptor agonists work primarily by:

• Slowing gastric emptying — Food stays in your stomach longer, creating prolonged satiety
• Central appetite suppression — Direct signaling in the hypothalamus and brainstem reduces hunger drive
• Improved insulin sensitivity — Better glucose handling, reduced lipogenesis
• Reduced food reward signaling — Cravings diminish, particularly for calorie-dense foods
• Possible direct lipolytic effects — Emerging evidence suggests some GLP-1 agonists may promote fat oxidation independent of caloric deficit

This is the most powerful fat loss mechanism available in 2026. The caloric deficit is automatic because you genuinely want to eat less.

Pathway 2: Direct Lipolysis (GH Fragments)

Growth hormone fragments and AOD-9604 work by:

• Directly stimulating lipolysis — Breaking triglycerides into free fatty acids and glycerol
• Inhibiting lipogenesis — Preventing new fat storage
• Targeting adipose tissue specifically — Without the metabolic/anabolic effects of full HGH
• No effect on appetite — You must still create a caloric deficit through diet/exercise

This pathway is weaker than GLP-1 agonists for total weight loss but may offer localized fat reduction benefits.

Pathway 3: Indirect GH Elevation (Secretagogues)

Growth hormone secretagogues increase your body's own GH production by:

• Stimulating the pituitary — Causing GH pulses (GHRH analogs) or triggering release (ghrelin mimetics)
• Elevating IGF-1 — Downstream growth factor that promotes body recomposition
• Improving sleep quality — Better GH secretion during deep sleep phases
• Gradual body recomposition — Fat loss + muscle gain simultaneously over months

This is the mildest pathway — producing subtle, gradual changes to body composition rather than dramatic weight loss.

---

Tier 1: Strongest Evidence, Largest Effect (GLP-1 and Multi-Agonists)

Semaglutide — The Standard Bearer

Mechanism: GLP-1 receptor agonist (single incretin) Brand names: Ozempic (diabetes), Wegovy (weight loss) Evidence level: Phase III clinical trials, FDA/Health Canada approved Average weight loss: 15-17% of body weight over 68 weeks (STEP 1 trial)

Semaglutide is the compound that broke fat loss peptides into mainstream consciousness. Its evidence base is enormous — thousands of patients across multiple Phase III trials with consistent, reproducible results.

How it works in practice:

• Week 1-4: Appetite noticeably reduced. Portion sizes naturally decrease.
• Week 4-8: Steady weight loss (1-2 lbs/week). Food noise disappears.
• Week 8-16: Continued linear weight loss. Body composition visibly changing.
• Week 16-68: Gradual but sustained loss. Most achieve 15%+ reduction.

Dosing protocol:

• Start: 0.25mg once weekly (weeks 1-4)
• Escalate: 0.5mg weekly (weeks 5-8)
• Escalate: 1.0mg weekly (weeks 9-12)
• Escalate: 1.7mg weekly (weeks 13-16)
• Maintenance: 2.4mg weekly (if tolerated)

Side effects: Nausea (most common, usually resolves), constipation, diarrhea, injection site reactions. Starting low and titrating slowly minimizes GI side effects.

Cost estimate (Canada, compounded): $150-300 CAD/month at maintenance dose

Who this is for: Anyone with significant fat to lose (BMI 27+), particularly those who struggle with appetite control, food cravings, or emotional eating. The strongest tool available for pure fat loss.

[Internal Link: /semaglutide/]

Tirzepatide — The Dual Agonist Upgrade

Mechanism: GLP-1 + GIP dual receptor agonist Brand names: Mounjaro (diabetes), Zepbound (weight loss) Evidence level: Phase III clinical trials, FDA/Health Canada approved Average weight loss: 20-22% of body weight over 72 weeks (SURMOUNT-1 trial)

Tirzepatide adds GIP (Glucose-dependent Insulinotropic Polypeptide) receptor activation to GLP-1 agonism. This dual mechanism produces approximately 25-30% greater weight loss than Semaglutide alone.

How it differs from Semaglutide:

• Slightly better tolerated (some studies show less nausea)
• Greater absolute weight loss at maximum doses
• Potentially better muscle preservation (emerging data)
• GIP receptor activation may enhance fat oxidation through distinct pathways

Dosing protocol:

• Start: 2.5mg once weekly (weeks 1-4)
• Escalate: 5mg weekly (weeks 5-8)
• Escalate: 7.5mg weekly (weeks 9-12)
• Escalate: 10mg weekly (weeks 13-16)
• Maximum: 15mg weekly (if needed)

Cost estimate (Canada, compounded): $200-400 CAD/month at maintenance dose

Who this is for: Users who want the maximum GLP-1 class fat loss, those who experienced intolerable nausea on Semaglutide, or those who plateaued on Semaglutide and want greater effect.

[Internal Link: /tirzepatide/]

Retatrutide — The Triple Agonist Frontier

Mechanism: GLP-1 + GIP + Glucagon triple receptor agonist Brand names: None yet (Phase III, expected approval 2026-2027) Evidence level: Phase II clinical trials (TRIUMPH-2 published) Average weight loss: 24-28% of body weight over 48 weeks (Phase II data)

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism. Glucagon directly increases energy expenditure and hepatic fat oxidation, creating a three-pronged attack on body fat.

Why this matters:

• 24-28% weight loss approaches what was previously only achievable through bariatric surgery
• Glucagon receptor activation increases basal metabolic rate (you burn more at rest)
• Faster onset of weight loss compared to Semaglutide
• Significant reduction in liver fat (potential NASH treatment)

Current status (2026):

• Phase III trials underway
• Available through research peptide suppliers as compounded formulation
• Not yet approved by FDA or Health Canada for clinical use
• Evidence is strong but not yet as robust as Semaglutide/Tirzepatide

Dosing protocol (based on Phase II):

• Start: 1mg once weekly (weeks 1-4)
• Escalate: 2mg weekly (weeks 5-8)
• Escalate: 4mg weekly (weeks 9-12)
• Escalate: 8mg weekly (weeks 13-16)
• Maximum: 12mg weekly (if tolerated)

Cost estimate (Canada, research-grade): $250-500 CAD/month

Who this is for: Users with significant obesity who have tried Semaglutide/Tirzepatide and want maximum effect, or those who need substantial weight loss (50+ lbs) and want the most aggressive pharmacological option available.

[Internal Link: /retatrutide/]

---

Tier 2: Solid Evidence, Moderate Effect (GH Fragments & Targeted Lipolysis)

HGH Fragment 176-191 — The Lipolysis Specialist

Mechanism: Direct lipolysis via modified GH peptide fragment (amino acids 176-191 of HGH) Evidence level: In-vitro studies, animal studies, limited human clinical data, extensive community anecdotal evidence Average fat loss: 2-4 lbs per month (when combined with caloric deficit)

HGH Fragment 176-191 is a modified segment of the human growth hormone molecule that retains the fat-burning properties of HGH while eliminating the growth-promoting and blood sugar effects.

How it works:

• Stimulates lipolysis (fat breakdown) by mimicking the way natural GH regulates fat metabolism
• Inhibits lipogenesis (new fat formation)
• Does NOT increase blood sugar (unlike full HGH)
• Does NOT promote muscle/organ growth (unlike full HGH)
• Does NOT affect sleep, hunger, or IGF-1 levels significantly

Dosing protocol:

• Standard: 250-500mcg per injection
• Frequency: 2-3 times daily (morning fasted + pre-cardio + bedtime)
• Must be injected on an empty stomach (food, especially carbohydrates, blunts the effect)
• Cycle: 8-12 weeks on, 4 weeks off

What it does NOT do:

• Does not suppress appetite — you still need diet discipline
• Does not produce dramatic scale changes — fat loss is gradual
• Does not work if you are in a caloric surplus (it mobilizes fat, but if you eat it back, net loss is zero)

Cost estimate (Canada): $80-150 CAD/month (5mg vials, multiple per month needed at 3x daily dosing)

Who this is for: Already lean individuals (12-18% body fat) trying to target stubborn fat areas. Useful for bodybuilders in contest prep or fitness enthusiasts who have already dialed in diet and want an additional 10-15% boost to fat oxidation.

[Internal Link: /hgh-fragment-176-191/]

AOD-9604 — The Commercialized Fragment

Mechanism: Synthetic analog of HGH Fragment 176-191 with additional stabilization Evidence level: Phase II clinical trials (completed in early 2000s), animal studies, TGA (Australia) approved for over-the-counter sale as food supplement Average fat loss: Similar to HGH Frag — 2-4 lbs per month with caloric deficit

AOD-9604 (Advanced Obesity Drug) was developed by Metabolic Pharmaceuticals in Australia. It is essentially an optimized version of HGH Fragment 176-191 with a tyrosine residue added for stability.

How it compares to HGH Fragment 176-191:

• Same mechanism of action (direct lipolysis, lipogenesis inhibition)
• Slightly more stable molecule (longer shelf life once reconstituted)
• More clinical trial data available (though the trials showed modest results)
• Approved as a food ingredient in Australia (the only country to grant this status)

The clinical trial reality: Phase II trials showed statistically significant fat loss versus placebo, but the absolute effect was modest (approximately 2.6 kg over 12 weeks at the highest dose). The company ultimately abandoned development because the effect, while real, was not commercially compelling compared to what GLP-1 agonists later achieved.

Dosing protocol:

• Standard: 250-300mcg per injection
• Frequency: Once daily (morning fasted) or twice daily for enhanced effect
• Must be fasted (same carbohydrate sensitivity as HGH Fragment)
• Cycle: 12 weeks on, 4 weeks off

Cost estimate (Canada): $100-180 CAD/month

Who this is for: Same profile as HGH Fragment users — lean individuals targeting stubborn fat. Some prefer AOD-9604 for its slightly better stability and clinical trial backing.

[Internal Link: /aod-9604/]

Tesamorelin — The Prescription GH-Releaser

Mechanism: GHRH (Growth Hormone-Releasing Hormone) analog — stimulates pulsatile GH release Brand name: Egrifta (approved for HIV-associated lipodystrophy) Evidence level: Phase III clinical trials, FDA approved (for specific indication) Average fat loss: Significant reduction in visceral adipose tissue (VAT) — 15-18% reduction in trunk fat over 26 weeks

Tesamorelin is unique in this list: it is an FDA-approved prescription medication with robust clinical evidence for reducing visceral (deep abdominal) fat specifically. It works by stimulating your pituitary to produce more growth hormone in natural pulses.

Why it is special:

• Targets visceral fat preferentially (the metabolically dangerous type)
• Maintains natural GH pulsatility (unlike exogenous HGH which creates constant levels)
• Does not significantly affect subcutaneous fat (the "pinchable" layer)
• Preserves or improves lean body mass while reducing fat mass

Dosing protocol:

• Standard: 2mg subcutaneous injection daily
• Timing: Before bed (enhances natural nocturnal GH secretion)
• Duration: 6-12 months for optimal results

Limitations:

• Expensive when prescribed ($800-1,500 CAD/month through pharmacy)
• Off-label use in Canada requires cooperative physician
• Research-grade compounded versions: $200-400 CAD/month
• Modest effect on subcutaneous fat (not ideal for bodybuilding contest prep)

Who this is for: Individuals with significant visceral fat (the "hard belly" that is not pinchable), metabolic syndrome markers, or those wanting to reduce cardiovascular risk through targeted visceral fat reduction.

[Internal Link: /tesamorelin/]

---

Tier 3: Supportive/Indirect Effect (GH Secretagogues for Body Recomposition)

CJC-1295 + Ipamorelin Stack — The Body Recomp Standard

Mechanism: GHRH analog (CJC-1295) + Ghrelin mimetic (Ipamorelin) = amplified pulsatile GH release Evidence level: Individual component clinical trials, extensive community evidence for the stack Average fat loss: 3-6 lbs over 3-6 months (as part of body recomposition — simultaneous fat loss and muscle gain)

This stack is not a fat loss tool in the way GLP-1 agonists are. It is a body recomposition tool. The elevated growth hormone promotes:

• Increased fat oxidation during sleep and fasted states
• Improved recovery allowing more training volume
• Gradual lean mass accrual
• Better sleep quality (which independently supports fat loss)
• Improved skin, hair, and joint health as secondary benefits

How the synergy works:

• CJC-1295 (no-DAC, also called Mod GRF 1-29) amplifies the GH pulse
• Ipamorelin triggers the GH pulse through ghrelin receptor stimulation
• Together they produce GH pulses 3-5x larger than either alone
• This mimics youthful GH secretion patterns

Dosing protocol:

• CJC-1295 (no-DAC): 100mcg per injection
• Ipamorelin: 200-300mcg per injection
• Combined injection: 2-3 times daily (morning fasted, post-workout, before bed)
• Before-bed dose is most important (enhances natural nocturnal GH peak)
• Must be fasted — food (especially carbohydrates and fats) blunts GH release

Timeline of results:

• Week 1-2: Improved sleep quality, more vivid dreams
• Week 2-4: Better recovery, slight increase in morning energy
• Month 1-2: Subtle body composition improvements (scale may not change as muscle replaces fat)
• Month 3-6: Visible recomposition — leaner appearance, improved muscle fullness, reduced stubborn fat areas

Cost estimate (Canada): $150-250 CAD/month (multiple vials of each needed for 2-3x daily dosing)

Who this is for: Already-active individuals (training 4-5x per week) who want gradual body recomposition rather than dramatic weight loss. Excellent for those within 10-20 lbs of their goal weight who want to "recomp" rather than cut. Popular with men 30-50 wanting to recapture youthful body composition.

[Internal Link: /cjc-1295/] [Internal Link: /ipamorelin/]

MK-677 (Ibutamoren) — The Oral GH Booster

Mechanism: Non-peptide ghrelin mimetic — stimulates GH release orally (no injection needed) Evidence level: Phase II clinical trials, extensive long-term human data Average fat loss: Minimal as standalone; primarily a recomposition/recovery tool Average lean mass gain: 1-3 lbs over 8-12 weeks

MK-677 is technically not a peptide — it is a non-peptide small molecule that mimics ghrelin. Its primary appeal is oral dosing (no injections) and 24-hour GH elevation from a single daily dose.

How it works:

• Stimulates the pituitary to release GH via ghrelin receptor activation
• Raises IGF-1 levels by 40-90% (dose dependent)
• Effects are sustained over months of continuous use without desensitization
• Half-life of ~24 hours allows once-daily oral dosing

The appetite paradox: MK-677 increases appetite in most users (it mimics ghrelin, the hunger hormone). This makes it counterproductive for pure fat loss unless you have the discipline to maintain a caloric deficit despite increased hunger. Many users actually gain weight on MK-677 — a combination of muscle, fat, and water.

Who actually loses fat on MK-677:

• Users who pair it with strict caloric tracking (the elevated GH partitions nutrients toward muscle)
• Users who combine it with fasted morning cardio (GH elevation enhances fat oxidation during fasted exercise)
• Users who prioritize sleep (MK-677 dramatically improves sleep quality, which supports cortisol management and fat loss)

Dosing protocol:

• Standard: 10-25mg once daily (oral)
• Timing: Before bed (reduces appetite impact, maximizes sleep-related GH benefits)
• Duration: 3-6 months continuously (no cycling needed — no hormonal suppression)
• Start at 10mg for 2 weeks, then increase to 25mg if tolerated

Side effects to manage:

• Increased appetite (primary challenge for fat loss users)
• Water retention (first 2-4 weeks, stabilizes)
• Numbness/tingling in hands (carpal tunnel-like, from IGF-1 elevation — dose dependent)
• Potential blood sugar impact (monitor fasting glucose if using long-term)

Cost estimate (Canada): $40-80 CAD/month (one of the most affordable options)

Who this is for: Users who refuse injections, those seeking general anti-aging and body composition improvement over months, athletes wanting enhanced recovery without injectable peptides. NOT ideal for users whose primary goal is rapid fat loss.

[Internal Link: /mk-677/]

---

Head-to-Head Comparison: Choosing Your Compound

By Primary Goal

By Monthly Cost (Canada, 2026)

By Evidence Quality

---

Stacking Considerations: Combining Fat Loss Peptides

Effective Stacks

Semaglutide + CJC-1295/Ipamorelin:

• Semaglutide handles appetite suppression and metabolic signaling
• CJC/Ipa preserves muscle mass through elevated GH during the caloric deficit
• Excellent combination for maximizing fat loss while minimizing muscle loss
• Common in Canadian bodybuilding and fitness communities

HGH Fragment + Cardio Protocol:

• HGH Fragment mobilizes fatty acids
• Fasted cardio (30-45 min post-injection) oxidizes the mobilized fatty acids
• Without the cardio, mobilized fat gets re-esterified (stored again)
• Timing is critical: inject 15-20 minutes before fasted AM cardio

Tirzepatide + MK-677 (before bed only):

• Tirzepatide drives fat loss through appetite suppression
• MK-677 at bedtime enhances sleep quality and GH for muscle preservation
• MK-677's appetite increase is managed by taking it at bedtime (sleeping through the hunger)
• Monitor blood sugar closely (both can affect glucose metabolism)

Stacks to Avoid

Semaglutide + MK-677 (daytime dosing):

• MK-677's appetite increase directly counteracts Semaglutide's appetite suppression
• You are paying for two compounds working against each other
• If combining, MK-677 must be bedtime only

Multiple GLP-1 Agonists Together:

• Semaglutide + Tirzepatide simultaneously is not beneficial — they compete for the same receptor
• Choose one or the other, not both
• Switching between them is fine; stacking is pointless

HGH Fragment + Full HGH:

• They share the same mechanism — Fragment is a piece of the HGH molecule
• Using both is redundant
• Choose full HGH (broader benefits, more expensive) or Fragment (targeted fat loss, cheaper)

---

Practical Protocols: Sample Fat Loss Programs

Protocol A: Aggressive Fat Loss (30+ lbs to lose)

Primary compound: Semaglutide (titrate to 1.7-2.4mg weekly) Support: CJC-1295 100mcg + Ipamorelin 200mcg before bed (muscle preservation) Duration: 6-12 months Expected result: 15-22% body weight reduction Monthly cost: $250-450 CAD Diet: Let appetite suppression guide intake naturally. Target 0.8g protein per pound of GOAL body weight minimum.

Protocol B: Stubborn Fat Targeting (Already <18% body fat, want 12%)

Primary compound: HGH Fragment 176-191 (250mcg 2-3x daily, fasted) Support: Fasted AM cardio 30-45 min, 5x/week Duration: 8-12 weeks Expected result: 4-8 lbs fat loss (significant visual change at already-low body fat levels) Monthly cost: $100-200 CAD Diet: Moderate caloric deficit (300-500 cal/day). High protein (1g per pound body weight).

Protocol C: Slow Body Recomposition (No rush, optimize over 6 months)

Primary compound: CJC-1295 100mcg + Ipamorelin 200mcg (2-3x daily) Support: MK-677 15-25mg before bed Duration: 4-6 months Expected result: 5-10 lbs fat loss + 3-5 lbs muscle gain (minimal scale change, significant visual change) Monthly cost: $200-300 CAD Diet: Maintenance calories or slight surplus. High protein. Prioritize sleep (8+ hours).

Protocol D: Budget Fat Loss (Maximum effect per dollar)

Primary compound: MK-677 25mg before bed + fasted AM cardio protocol Support: Strict caloric deficit (500-750 cal/day), high protein, daily step count (10K+) Duration: 3-6 months Expected result: Modest recomposition (5-8 lbs fat loss if diet is disciplined) Monthly cost: $40-80 CAD Diet: Strict tracking mandatory. MK-677 increases hunger — you must out-discipline it.

---

Canadian-Specific Considerations

Legal Status (2026)

• Semaglutide/Tirzepatide: Prescription medications in Canada. Available through physicians, telehealth (Felix, Maple), or compounding pharmacies with prescription.
• Retatrutide: Not approved. Available through research peptide suppliers.
• HGH Fragment/AOD-9604/CJC-1295/Ipamorelin: Not scheduled substances. Available through research peptide suppliers.
• MK-677: Not a peptide, sold as research compound. Available through supplement-adjacent retailers and research chemical suppliers.

Sourcing Quality Peptides in Canada

• Demand third-party testing (HPLC purity + mass spectrometry identity confirmation)
• Canadian-based suppliers reduce customs risk
• Peptides are not prohibited to possess for personal use in Canada
• Storage: refrigerate upon receipt, protect from light, use within 30 days of reconstitution

Healthcare Coverage

• GLP-1 agonists (Semaglutide, Tirzepatide) may be partially covered by private insurance if prescribed for type 2 diabetes or BMI > 30
• Weight loss indication coverage is expanding across Canadian private insurers
• Research-grade peptides are never covered by insurance
• Telehealth prescriptions for GLP-1 agonists are increasingly available (Felix Health, Maple, Rocket Doctor)

---

Frequently Asked Questions

Can I use fat loss peptides without changing my diet?

GLP-1 agonists (Semaglutide, Tirzepatide, Retatrutide) will reduce your appetite enough that you naturally eat less — so technically yes, they produce results without conscious dieting. However, optimizing protein intake (to preserve muscle) will dramatically improve your body composition outcomes. For all other peptides (HGH Fragment, AOD, CJC/Ipa, MK-677), a deliberate caloric deficit is absolutely required. These compounds enhance fat loss; they do not create it.

How long do I need to stay on Semaglutide to keep the weight off?

Current evidence shows that most weight regain occurs within 12 months of discontinuation. The long-term strategy is either indefinite low-dose maintenance (0.5-1.0mg weekly) or a structured "step-down" approach where you build sustainable habits during the active phase and then taper very slowly over 6+ months while your appetite recalibrates.

Will fat loss peptides cause muscle loss?

GLP-1 agonists at high doses with rapid weight loss can cause lean mass loss (20-40% of total weight lost may be lean mass in studies). This is mitigated by high protein intake (1g per pound goal body weight), resistance training 3-4x weekly, and potentially stacking with GH-elevating peptides (CJC/Ipa). HGH-pathway peptides generally preserve or build lean mass by design.

Are there any fat loss peptides safe for women?

All peptides listed in this article are used by women. GLP-1 agonists are prescribed equally to both sexes with the same protocols. HGH fragments, AOD-9604, and CJC/Ipa are non-androgenic and safe for female use. MK-677 is also used by women at the same doses (10-25mg). None of these compounds cause virilization or androgenic side effects.

What is the fastest fat loss peptide protocol available?

Retatrutide at maximum dose (12mg weekly) has produced the fastest documented fat loss in clinical trials — approximately 24-28% body weight reduction in 48 weeks, with significant early-phase losses. Tirzepatide at 15mg weekly is the fastest approved option. For context: this level of fat loss previously required bariatric surgery.

---

Conclusion: Match the Tool to the Job

Fat loss peptides exist on a spectrum from mild body recomposition support to surgical-level weight loss. The right choice depends on:

1. How much fat you need to lose — 50+ lbs calls for Tier 1 GLP-1 agonists. 10-15 lbs calls for Tier 2-3 recomp tools.
2. Your timeline — Need results in 3 months? GLP-1 agonists. Happy with gradual change over 6-12 months? CJC/Ipa or MK-677.
3. Your budget — $40/month? MK-677. $300/month? Semaglutide. $500/month? Retatrutide + CJC/Ipa stack.
4. Your willingness to diet — Cannot stick to a diet? Only GLP-1 agonists work without deliberate restriction. Everything else requires caloric deficit discipline.
5. Injection tolerance — Hate needles? MK-677 (oral) or weekly GLP-1 injections (one shot per week vs. 2-3 daily for secretagogues/fragments).

The peptide landscape for fat loss will continue evolving. Newer multi-agonists (survodutide, orforglipron, amycretin) are in late-stage trials. But as of 2026, the compounds ranked above represent the best available tools for pharmacological fat loss — each backed by real evidence, available to Canadians, and serving a distinct use case.

Choose your tool. Execute the protocol. Let the results follow.

[Internal Link: /weight-loss-peptides/] [Internal Link: /peptide-starter-kit/]